Extension study for people finishing prior P1101 treatment
Part of Blood & lymphatic, Cancer clinical trials.
This is an “extension” trial for people who already completed a 52-week P1101 study and agreed to continue. It tests whether continuing P1101 after the original study is safe and beneficial for certain patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the full 52-week treatment in the earlier study (A19-201).
- Your study doctor must think it’s OK for you to join this extension.
- You must be able and willing to sign written informed consent for this study.
- You must not be judged by your study doctor as not eligible to continue P1101.
- Your current health and prior response must be acceptable for continued P1101 treatment (as decided by the study team).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug, PRT12396, for people with certain blood cancers (polycythemia vera or myelofibrosis) that have a specific JAK2 mutation. It aims to see if the drug is safe and starts to work against the disease.
This trial tests a combination of two drugs—gecacitinib (a JAK inhibitor) and pegylated interferon—to see if they work better together for people with polycythemia vera (PV), a blood cancer that causes too many red blood cells. The study is for patients who have not tried these specific treatments before and who have symptoms like high blood counts, weight loss, night sweats, or an enlarged spleen.
This study checks whether continuing ASTX727 for people who already benefited from it in an earlier Taiho study is safe and effective. It may be an option if you stayed on ASTX727 at the end of your parent study and your doctor felt it was helping you.
This trial tests a new drug called 9MW3011 for people with polycythemia vera (PV) who haven't done well on or can't take standard treatments like hydroxyurea or interferon. The goal is to see if the drug is safe and how it works in your body.
This trial tests two new drugs, P1101 and P1801, in people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination is safe and effective.
This trial tests a combination of two medications, ropeginterferon alfa-2b and ruxolitinib, for people with myelofibrosis whose spleen has not shrunk enough or has grown back while on ruxolitinib. The goal is to see if adding the newer drug can improve outcomes.
Hear when a new Polycythemia Vera (PV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.